arrow
E

Edwin R. Parra

The University of Texas MD Anderson Cancer Center
H指数:61
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence

纳武利尤单抗联合伊匹木单抗诱导肾髓质癌发生超进展:一项II期试验结果及临床前证据

2025-11-250
OAAI
Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapy

作者更正:PPP2R1A基因突变预示着癌症免疫疗法后的生存改善

Nature
IF48.5
2025-09-050
OAAI
PPP2R1A mutations portend improved survival after cancer immunotherapy

PPP2R1A突变预示癌症免疫治疗后生存率提高

Nature
IF48.5
2025-07-020
OA
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception

人类和小鼠肺腺癌前体物的空间与多组学分析揭示TIM-3可作为癌症拦截的潜在靶点

2025-05-080
OA
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial

在抗PD-L1治疗的 Newly Diagnosed Glioblastoma 患者队列中,总体生存率的改善与特定的免疫、突变和肠道微生物组特征相关:一项单臂前瞻性I/II期试验

2025-04-270
OA
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial

帕博利珠单抗联合化疗在晚期卵巢癌一线治疗中的应用:一项II期临床试验的临床与转化研究结果

MED
IF11.8
2025-01-010
PRE
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

CTLA4阻断消除KEAP1/STK11-related对PD-(L)1抑制剂的抗性

Nature
IF48.5
2024-10-090
OAAI
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas

异柠檬酸脱氢酶分层的原发性和复发性人类神经胶质瘤的免疫景观

2024-08-100
PRE
An atlas of epithelial cell states and plasticity in lung adenocarcinoma

肺腺癌上皮细胞状态和可塑性的图谱

Nature
IF48.5
2024-02-280
OAAI
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma
2024-02-1310
PRE
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
2024-01-265
OAAI
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study
CANCER
IF5.1
2023-11-204
PRE
Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations

胸膜间皮瘤对新辅助治疗的影像学反应应作为患者选择减瘤手术的指南

2023-08-110
OAAI
Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNg-expressing CD8 T cells

CD19 CAR T细胞治疗后的长期血细胞减少与克隆扩增的表达IFNg的CD8 T细胞的骨髓浸润有关

2023-08-0121
OAAI